Nanoscope Therapeutics Inc.

We are pleased to announce that Nanoscope Therapeutics Inc. will be presenting at the H.C. Wainwright & Co., LLC 3rd Annual BioConnect Showcase at The Sanctuary, Kiawah Island, SC.  CEO Sulagna Bhattacharya will make a Company Presentation on Monday, March 17th, 2025 at 9:40am ET in the Grand Oaks Ballroom. Join us as we share the latest advancements in our pioneering gene therapy for inherited retinal diseases and discuss how we’re working to restore vision for patients with unmet medical needs. The executive team will be available to meet with investors during the event. Feel free to connect with us if you’ll be attending! Read the full press release here: https://lnkd.in/g2fT_iKZ Learn more about Nanoscope at our website: nanostherapeutics.com #Biotech #GeneTherapy #Innovation #NanoscopeTherapeutics #HCWBioconnectShowcase

Nanoscope Therapeutics Inc. CEO and Co-founder, Sulagna Bhattacharya, is honored to be invited to participate in a ”Spotlight" at the Bernstein Private Wealth Management Life Sciences and Healthcare Study Group taking place March 11-12 in Boston. For more information about Nanoscope visit: Nanostherapeutics.com #genetherapy #cureblindness #ophthalmology 

We are proud to see our CEO & Co-founder Sulagna Bhattacharya included in this incredible group of women who bring passion and commitment to the important work they do. Each one is an inspiration! https://lnkd.in/gfUh__w7

Nanoscope is extremely proud to announce that Ramesh Arjunji, PhD, has joined our team as EVP of Value and Access. Dr. Arjunji brings a breadth of experience including commercialization, R&D, medical affairs and business development gained from various leadership positions in the biopharmaceutical industry. We are excited to have his expertise and passion on our team. “In addition to his diverse industry experience spanning ophthalmology, neurology, oncology, immunology and medical devices, Ramesh has been an important market access leader for some of the most successfully commercialized gene therapies. We look forward to his contributions as we make preparations to launch MCO-010 as the first restorative treatment for retinitis pigmentosa patients,” said Sulagna Bhattacharya, Co-Founder and CEO of Nanoscope Therapeutics Inc. To learn more about Nanoscope and Dr. Arjunji read the full release: https://lnkd.in/gVDEVAJK #leadership #genetherapy #retinitispigmentosa #stargardt #ophthalmology Samarendra Mohanty Samuel B Barone Sunil Gupta, MD

Samarendra Mohanty, PhD, Co-founder, President & Chief Scientific Officer of Nanoscope Therapeutics Inc. will be participating in the Cell and Gene Therapy Summit on March 4 in San Francisco. He will be a panelist on: "The Cell & Gene Therapy Journey: Discovery to Commercialization” where he will provide valuable insights into the challenges and breakthroughs shaping the path from research to real-world applications. Dr. Mohanty will be joined on the panel by: Annalisa Lattanzi, Kamau Therapeutics; Max DeLong, Genentech; Gai Ayalon, FOXG1 Research Foundation; Franz Gerner, South Mountain Advanced Therapies and James Cody, Charles River Laboratories . The panel takes place on March 4th from 11:00 -11:45am PST in the Liberty Ballroom. To learn more about Nanoscope Therapeutics, a biotechnology company committed to restoring vision in blind patients in real-world settings by developing and commercializing novel gene therapies for retinal degenerative diseases, visit our website: nanostherapeutics.com #GeneTherapy #ophthalmology #leadership.

This week, Nanoscope President & Chief Scientific Officer Samarendra Mohanty travels to California for the USC Engineered Vision Symposium. The symposium takes place March 3-4 at the Torrance Marriott Redondo Beach. Dr. Mohanty will deliver a Plenary presentation: “Mutation-agnostic gene therapies for ocular disorders” on Monday from 3:30 to 3:55pm. For more information about the Symposium: https://lnkd.in/gAKwWCkv Tags: University of Southern California, USC Ginsburg Institute for Biomedical Therapeutics, USC Roski Eye Institute, USC Viterbi School of Engineering, Nanoscope Therapeutics Inc.

Today, on Rare Disease Day, we stand in solidarity with the hundreds of millions affected by rare diseases worldwide. At Nanoscope Therapeutics, our mission is to bring sight-restoring optogenetic therapies to patients blinded by inherited retinal diseases (IRDs)—a group of rare conditions with very limited treatment options. Every breakthrough in science brings us closer to a future of restored vision and renewed hope for those living with impaired vision and blindness due to IRDs. We remain committed to advancing innovative treatments and advocating for the rare disease community. Join the entire Nanoscope team in raising awareness and supporting the fight against rare diseases! Learn more about us at nanostherapeutics.com Nanoscope Therapeutics Inc. Sulagna Bhattacharya, Samarendra Mohanty, Samuel B Barone, Raymond Kaczmarek, Naj Sharif, Glenn Sblendorio, Sunil Gupta, MD, Khandan Baradaran, PhD  #RareDiseaseDay #lightupforrare #retinitispigmentosa #stargardt #ophthalmology

We’re thrilled to announce that Najam (Naj) Sharif, PhD, DSc, our VP of Global Research and Development at Nanoscope Therapeutics Inc., will be participating in the Texas BioLife Summit 2025! Dr. Sharif will share his deep expertise in drug discovery and development as moderator and participant on the panel: Setting the Stage with Preclinical Work at 9:00am on Thursday, February 27. The event will take place at the Hilton Anatole Hotel in Dallas. Nanoscope Therapeutics is proud to be part of the dynamic and growing Texas biotech industry. Join us at #TexasBioLifeSummit2025 to connect, collaborate, and explore the future of biotech innovation in Texas. For more information about Nanoscope Therapeutics: nanostherapeutics.com #Biotechnology #GeneTherapy #Retina #Texas